174 related articles for article (PubMed ID: 17268792)
1. Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma.
Diaconu NC; Kaminska R; Naukkarinen A; Harvima RJ; Nilsson G; Harvima IT
Cancer Immunol Immunother; 2007 Sep; 56(9):1407-15. PubMed ID: 17268792
[TBL] [Abstract][Full Text] [Related]
2. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.
Cerutti A; Schaffer A; Goodwin RG; Shah S; Zan H; Ely S; Casali P
J Immunol; 2000 Jul; 165(2):786-94. PubMed ID: 10878352
[TBL] [Abstract][Full Text] [Related]
3. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.
Molin D; Fischer M; Xiang Z; Larsson U; Harvima I; Venge P; Nilsson K; Sundström C; Enblad G; Nilsson G
Br J Haematol; 2001 Sep; 114(3):616-23. PubMed ID: 11552987
[TBL] [Abstract][Full Text] [Related]
4. The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.
Diaconu NC; Kaminska R; Naukkarinen A; Harvima RJ; Harvima IT
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):908-15. PubMed ID: 17658999
[TBL] [Abstract][Full Text] [Related]
5. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.
Gruss HJ; Duyster J; Herrmann F
Ann Oncol; 1996; 7 Suppl 4():19-26. PubMed ID: 8836404
[TBL] [Abstract][Full Text] [Related]
6. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.
Gruss HJ; Ulrich D; Braddy S; Armitage RJ; Dower SK
Eur J Immunol; 1995 Jul; 25(7):2083-9. PubMed ID: 7621881
[TBL] [Abstract][Full Text] [Related]
7. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.
Fischer M; Harvima IT; Carvalho RF; Möller C; Naukkarinen A; Enblad G; Nilsson G
J Clin Invest; 2006 Oct; 116(10):2748-56. PubMed ID: 16964309
[TBL] [Abstract][Full Text] [Related]
8. Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps.
Zhai GT; Li JX; Zhang XH; Liao B; Lu X; Liu Z
Laryngoscope; 2019 Mar; 129(3):E110-E117. PubMed ID: 30570137
[TBL] [Abstract][Full Text] [Related]
9. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES.
Aoki M; Pawankar R; Niimi Y; Kawana S
Int Arch Allergy Immunol; 2003 Mar; 130(3):216-23. PubMed ID: 12660426
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity to CYP24A1, but not vitamin D receptor, is increased in mast cells of keratinocyte skin cancers.
Kaukinen A; Siiskonen H; Pelkonen J; Harvima IT
Eur J Dermatol; 2017 Dec; 27(6):590-598. PubMed ID: 29165303
[TBL] [Abstract][Full Text] [Related]
11. Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas.
Phillips TA; Ni J; Hunt JS
J Leukoc Biol; 2003 Jul; 74(1):81-7. PubMed ID: 12832445
[TBL] [Abstract][Full Text] [Related]
12. Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Trentin L; Facco M; Siviero M; Galvan S; Piazza F; Perin A; Agostini C; Semenzato G
Blood; 2000 Jul; 96(2):647-54. PubMed ID: 10887130
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.
Gruss HJ; Dower SK
Blood; 1995 Jun; 85(12):3378-404. PubMed ID: 7780126
[TBL] [Abstract][Full Text] [Related]
14. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.
Mori M; Manuelli C; Pimpinelli N; Mavilia C; Maggi E; Santucci M; Bianchi B; Cappugi P; Giannotti B; Kadin ME
Blood; 1999 Nov; 94(9):3077-83. PubMed ID: 10556192
[TBL] [Abstract][Full Text] [Related]
15. CD30L/CD30 is critical for maintenance of IL-17A-producing γδ T cells bearing Vγ6 in mucosa-associated tissues in mice.
Sun X; Shibata K; Yamada H; Guo Y; Muta H; Podack ER; Yoshikai Y
Mucosal Immunol; 2013 Nov; 6(6):1191-201. PubMed ID: 23549449
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.
Oflazoglu E; Grewal IS; Gerber H
Adv Exp Med Biol; 2009; 647():174-85. PubMed ID: 19760074
[TBL] [Abstract][Full Text] [Related]
17. CD153 in rheumatoid arthritis: detection of a soluble form in serum and synovial fluid, and expression by mast cells in the rheumatic synovium.
Carvalho RF; Ulfgren AK; Engström M; Klint Ea; Nilsson G
J Rheumatol; 2009 Mar; 36(3):501-7. PubMed ID: 19208589
[TBL] [Abstract][Full Text] [Related]
18. Deciphering CD30 ligand biology and its role in humoral immunity.
Kennedy MK; Willis CR; Armitage RJ
Immunology; 2006 Jun; 118(2):143-52. PubMed ID: 16771849
[TBL] [Abstract][Full Text] [Related]
19. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation.
Carvalho RF; Nilsson G; Harvima IT
Exp Dermatol; 2010 Feb; 19(2):117-22. PubMed ID: 19889021
[TBL] [Abstract][Full Text] [Related]
20. The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response.
Marín ND; García LF
Tuberculosis (Edinb); 2017 Jan; 102():8-15. PubMed ID: 28061955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
